Neuroblastoma is a highly heterogeneous tumor of young children. Although many advances have been made towards understanding the molecular mechanisms dictating the phenotypic heterogeneity, the prognosis of children with neuroblastoma, particularly of progressively growing variants, has remained dire. About 10% of neuroblastomas regress spontaneously, probably by apoptosis, while another 20% have amplified the MYCN gene resulting in a poor prognosis. In pursuit of identifying cell deathassociated genes in neuroblastoma, we encountered the SCA2 gene, coding for ataxin-2, as an important player. Here, we report that enforced expression of wild-type ataxin-2, but not of mutant ataxin-2, sensitizes neuroblastoma cells for apoptosis. In line with this, higher levels of ataxin-2 were detected in apoptotic cells compared to nonapoptotic cells. Neuroblastoma tumors with amplified MYCN contain significantly less ataxin-2 protein than tumors without amplified MYCN. Collectively, our data suggest that ataxin-2 has an important role in regulating the susceptibility of neuroblastoma cells to apoptotic stimuli in vitro and in vivo.
Introduction
Neuroblastoma, a common pediatric tumor originating from neuroectodermal cells of the neural crest, has the highest rate of spontaneous regression among all tumors. Complete disappearance of the tumor without therapeutic interference is observed in about 10% of all cases and has been postulated to be a result of delayed apoptosis (Pritchard and Hickman, 1994) . Massive apoptosis has been detected in primary neuroblastomas (Ikeda et al., 1996) , and high expression levels of proapoptotic proteins such as caspases 1 and 3 (Nakagawara et al., 1997) correlate with a good prognosis. In contrast, neuroblastomas with amplified MYCN gene often have deletion or silencing of the CASP8 gene (Teitz et al., 2000) . Caspase-8, an initiator caspase and part of the death-inducing signaling complex, is now considered to act as a tumor suppressor in neuroblastoma (Teitz et al., 2001) . The oncogenic transcription factor MYCN plays an ambivalent role in neuroblastoma. Amplification of the MYCN gene with the consequence of enhanced expression occurs in about 20% of tumors (Savelyeva and Schwab, 2001 ) and leads to very aggressive tumors that withstand therapy, suggesting an unfavorable outcome (Berthold et al., 1990) . This deregulated expression of MYCN induces the transcription of genes that are implicated in cellular proliferation such as ODC, PTMA (Lutz et al., 1996) and genes involved in protein biosynthesis (Boon et al., 2001) . In experimental systems, the enhanced expression of MYCN sensitizes neuroblastoma cells for apoptosis, resulting in efficient cell death following exposure to cytostatic drugs at concentrations used in neuroblastoma therapy (Lutz et al., 1998; Fulda et al., 1999) .
However, neuroblastoma tumors are often therapy resistant in spite of high MYCN expression, indicating that neuroblastomas with amplified MYCN may have acquired defects in the molecular pathways governing apoptosis execution, although the molecular mechanisms by which apoptosis is induced in neuroblastoma remain elusive. Previous studies have focused on the expression status of known apoptosis-related genes (Teitz et al., 2000; Catchpoole and Lock, 2001) . We have taken a functional approach that should allow to define the role of genes involved in the regulation and/or execution of apoptosis in neuroblastoma. Using a neuroblastoma cell model, in which MYCN is necessary for apoptosis (Lutz et al., 1998) , we constructed a subtractive cDNA library enriched for putative proapoptotic genes. Among a multitude of genes differentially expressed in cells triggered to undergo apoptosis (preapoptotic cells), we encountered SCA2, which previously had been identified as the gene mutated in spinocerebellar ataxia type 2 (SCA2) (Imbert et al., 1996; Pulst et al., 1996; Sanpei et al., 1996) . SCA2 is a hereditary neurodegenerative disease correlated with the expansion of a CAG stretch in patient DNA. The expansion results in an extended polyglutamine tract of ataxin-2, a highly basic protein with an apparent molecular mass of 145 kDa (Huynh et al., 2000) and unknown wild-type function. SCA2 is mainly characterized by loss of pontine and olivary nuclei and of Purkinje cells in the cerebellum (Estrada et al., 1999) .
Here, we report that ataxin-2 is highly expressed in preapoptotic neuroblastoma cells and in neuroblastoma tumors without amplified MYCN, whereas expression in MYCN-amplified tumors is low. Ectopic expression of wild-type ataxin-2, but not of mutant ataxin-2, efficiently sensitizes neuroblastoma cells for apoptosis. Collectively, our data suggest ataxin-2 as an important regulator of the sensitivity of neuroblastoma cells to apoptotic stimuli.
Results
Subtractive cDNA library reveals putative cell deathassociated genes Tet21N neuroblastoma cells harboring a tetracyclinerepressable MYCN transgene were employed as the apoptosis model for neuroblastoma (Lutz et al., 1998) . In serum-starved MYCN-expressing Tet21N cells, apoptosis is triggered by interferon-g (IFNg). In order to identify cell death-associated genes in Tet21N cells, a subtractive cDNA library of preapoptotic versus nonapoptotic cells was constructed and cloned. The tester cDNA fraction was derived from MYCN-expressing cells that had been exposed to IFNg in growth-factordeprived culture medium (0.5% FCS) for 2-48 h (preapoptotic cells). The driver cDNA fraction originated from equally treated cells that had not been exposed to IFNg. Sequencing of 50 randomly picked clones revealed that the library, as expected, was enriched for known IFNg-induced genes such as IRF-1,WARS and RING4 (Table 1) . However, the majority of detected genes, for example, SCA2, CDK9 and FLNA, had not been previously described as either IFNg target genes or cell death-associated genes.
Ataxin-2 is upregulated in preapoptotic neuroblastoma cells
In order to discriminate between IFNg targets without effect on cell death and genes governing apoptosis, we tested several candidate genes for differential expression at various time points after induction of apoptosis by IFNg in MYCN-expressing Tet21N cells. Northern blot analysis showed that typical IFNg target genes were found highly upregulated within 2-9 h after exposure to IFNg (Table 1) , also in culture medium containing 10% FCS (data not shown). Similarly, cathepsin B, dynamin and filamin were induced 4 h after induction of apoptosis while the expression level of dihydroxyacetone phosphate acyltransferase (DAPAT) remained stable throughout the time course (Figure 1a) . In contrast, upregulated ataxin-2 mRNA was not seen before 24 h after exposure to IFNg. In control cells that had been cultivated for 24 h in 0.5% FCS without IFNg, upregulation was substantially lower. A similar expression course was seen for CDK9, a cdc2-related kinase (de Falco and Giordano, 1998) . We conclude that both SCA2 and CDK9 are not direct IFNg target genes.
As the activation was stronger for SCA2 than for CDK9, we went on to further determine if ataxin-2 has a role in apoptosis. Immunodetection with a monoclonal antibody directed against ataxin-2 established the enhanced expression of ataxin-2 protein in Tet21N cells 24 h after induction of apoptosis (Figure 1b) . The fulllength ataxin-2 protein appeared at 150 kDa. Ataxin-2 upregulation coincided with the appearance of activated caspase-8 (Figure 1b ).
Ectopic expression of wild-type ataxin-2 sensitizes neuroblastoma cells for apoptosis
To test if elevated ataxin-2 expression has an effect on apoptosis, we stably transfected Tet21N cells with an ataxin-2 expression construct with 22 CAG repeats (Sca2CAG22), which is the most common wild-type allele. Expression of the transgene was shown by RT-PCR using a primer pair that spans the CAG tract ( Figure 2a ) and by immunofluorescence using a FITC-coupled a-Xpresst antibody that recognizes the . Trypan blue exclusion revealed that the proportion of viable MYCN-expressing Tet21N-Sca2CAG22 cells dropped to little more than 40% after 6 days of culture in 0.5% FCS while the number of Tet21N-Zeo cells increased to more than 300% during the same time period (Figure 3b ). DNA extracted from Tet21N-Sca2CAG22 cells that had been cultivated in 0.5% FCS for 4 days showed ladder formation, a hallmark of apoptosis, while DNA from control cells remained intact ( Figure 3c ). In summary, ectopically expressed wild-type ataxin-2 efficiently sensitizes Tet21N cells for apoptosis triggered by growth factor deprivation.
Mutation of the polyglutamine tract reduces the proapoptotic activity of ataxin-2
To determine if mutation of the polyglutamine tract has an effect on the proapoptotic function of ataxin-2, we generated expression constructs encoding two CAG repeat variants. One construct (Sca2CAG79) encompassed an expanded CAG tract with 79 repeats, which was derived from an SCA2 patient with juvenile onset of the disease. The other construct contained a reduction to only one CAG trinucleotide, which is equivalent to the situation in murine ataxin-2 (Nechiporuk et al., 1998) . Tet21N cells were transfected, and stable clones were selected. Although equal cell numbers were transfected, the number of resulting Tet21N-Sca2-CAG79 and Tet21N-Sca2CAG1 colonies was substantially higher than the number of Tet21N-Sca2CAG22 colonies but lower than the number of Tet21N-Zeo colonies (data not shown). Expression of the different ataxin-2 alleles was determined by RT-PCR ( Figure 2a ) and immunofluorescence ( Figure 2b ). Using the aXpresst antibody, we detected cytoplasmic staining of comparable intensity in Tet21N-Sca2CAG22, Tet21N-Sca2CAG79 and Tet21N-Sca2CAGl cells.
Trypan blue exclusion revealed that Tet21N-Sca2-CAG79 and Tet21N-Sca2CAGl cells, unlike Tet21N-Sca2CAG22 cells (Figure 3b ), were able to proliferate in culture medium containing 0.5% FCS (data not shown). MTT assays in medium with 0.5% FCS showed that the rate of cell death in Tet21N-Sca2CAG79 cells was Figure 3d ). Collectively, in the human neuroblastoma cell system we are using, ataxin-2 protein with a mutated polyglutamine tract is less effective in sensitizing Tet21N cells for apoptosis than the wild-type protein. Caspase activation is necessary for most apoptotic processes (Green, 2000) . In order to test if ataxin-2-mediated apoptosis requires active caspases, Tet21N-Sca2CAG22 cells were cultivated for 3 days in 0.5% FCS in the presence or absence of zVAD-fmk, a broadrange caspase inhibitor. We also tested a specific cathepsin B inhibitor (zFA-fmk), as cathepsin B has been shown to function as an effector protease in apoptosis when released from lysosomes (Foghsgaard et al., 2001) . The proportion of cell death in Tet21N-Sca2CAG22 cells was 3174% compared to 1572% in Tet21N-Zeo (Figure 3e ). Addition of IFNg increased the proportion to 6974% (Tet21N-Zeo: 29%). Caspase inhibition with zVAD-fmk led to a strong reduction of cell death in Tet21N-Sca2CAG22 cells (1572%).
In contrast, inhibition of cathepsin B with zFA-fmk slightly increased the number of dead cells in both Tet21N-Sca2CAG22 and Tet21N-Zeo cells. We conclude that caspase activation is necessary for ataxin-2-mediated cell death.
Role of MYCN in ataxin-2-mediated apoptosis depends on cell density
Previous studies have shown that Tet21N cells require MYCN protein for apoptosis triggered by IFNg and serum withdrawal (Lutz et al., 1998) . In line with this, confluent Tet21N-Sca2CAG22 cells not expressing MYCN were resistant to cell death triggered by IFNg and serum withdrawal, whereas confluent cultures of MYCN-expressing cells underwent apoptosis (data not shown). However, in subconfluent Tet21N-Sca2CAG22 cultures, cell death after serum withdrawal was evident in both MYCN-expressing and -nonexpressing cells (Figure 3a) . (Figure 4 ). In contrast to trypan blue assays, where the medium was replaced after 3 days, thereby allowing continued proliferation of Tet21N-Zeo cells in medium with 0.5% FCS (Figure 3b ), the culture medium was not changed during the MTT assays. Taken together, MYCN expression is only required for apoptosis of confluent Tet21N-Sca2CAG22 cells, while it is dispensable in subconfluent cells.
Ataxin-2 expression in neuroblastoma tumors
Protein from cryopreserved neuroblastoma tumors was analysed by Western blotting for ataxin-2 protein expression. Initially, two stage-4s neuroblastomas without amplified MYCN, two low-stage neuroblastomas without amplified MYCN and two MYCN-amplified tumors were compared. The 4s tumors had the highest ataxin-2 protein expression (Figure 5a , nos. 1, 2). The tumors without amplification had reduced but readily detectable amounts of ataxin-2 (Figure 5a , nos. 3, 4) while the MYCN-amplified tumors contained only minute amounts of ataxin-2 protein (Figure 5a , nos. 5, 6). The ataxin-2 protein levels of individual tumors were classified as high (nos. 1, 2, 3), moderate (no. 4) or low (nos. 5, 6).
Subsequently, we compared tumors according to their MYCN status irrespective of stage, as amplified MYCN is an independent marker for prognosis. Most nonamplified tumors had high ataxin-2 expression (nos. 7, 9, 15, 16, 17, 23) , only in few tumors (nos. 8, 18, 24) moderate ataxin-2 protein expression was detectable. In contrast, of the tumors with amplified MYCN, only one (no. 21) had high expression of ataxin-2 protein.
Additionally, expression of procaspase-8 (Figure 5a ) and procaspase-3 (data not shown) was high in this tumor. Three MYCN-amplified tumors had moderate amounts of ataxin-2 protein (nos. 11, 13, 22) , while the majority (nos. 10, 12, 14, 19, 20) had low levels of ataxin-2. Overall, ataxin-2 protein levels in neuroblastoma tumors with amplified MYCN tend to be lower than in tumors without amplified MYCN. Seven of 11 neuroblastomas with amplified MYCN (64%) had undetectable or barely detectable ataxin-2 protein, while all 13 tested neuroblastomas without amplified MYCN had readily detectable ataxin-2 protein. In comparison, five of eight (62%) analysed tumors with amplified MYCN had low levels of procaspase-8 protein. Low procaspase-8 protein expression was detected in one of six (17%) analysed tumors without amplified MYCN.
A similar correlation between amplified MYCN and low ataxin-2 protein expression emerged for the analysis of neuroblastoma cell lines. Kelly, CHP-134 and NGP cells had considerably less ataxin-2 protein than the SH-EP cell line or non-neuroblastoma cells such as 293 embryonic kidney cells (Figure 5b ) and HeLa cells (data not shown). In Tet21N cells, MYCN expression did not reduce the level of ataxin-2 protein (data not shown). In summary, high MYCN copy numbers with the consequence of enhanced MYCN expression correlate with low levels of ataxin-2 protein in vivo and in vitro, while cells with a diploid MYCN status have high ataxin-2 expression.
Discussion
The study presented here has identified ataxin-2 as a proapoptotic member of the apoptosis-regulating pathways in human neuroblastoma cells. This role of ataxin-2 was discovered by the systematic characterization of a subtractive cDNA library enriched for genes that are preferentially expressed in preapoptotic Tet21N neuroblastoma cells. The Tet21N cell line presents a suitable model for deciphering the molecular pathways of apoptosis in neuroblastoma, as it combines conditional expression of the MYCN gene, a key player in neuroblastoma development, with efficient induction of apoptosis by IFNg in cells expressing MYCN. Cellular responses to IFNg activate numerous transcripts, only some of which have a proapoptotic function (reviewed in Boehm et al., 1997; Stark et al., 1998) . In Tet21N cells, direct IFNg target genes without apparent apoptosis-promoting function are characterized by rapid induction after 2-9 h following exposure, strong upregulation and induction by IFNg in the presence of growth factors. In contrast, late induction of ataxin-2 (after 24 h) and moderate upregulation establish that ataxin-2 is not directly activated by IFNg. Instead, elevated transcription of ataxin-2 coincides with the appearance of apoptotic cells (detectable after 24-48 h) and activated caspase 8. Ectopic expression of wild-type ataxin-2 in Tet21N cells had a profound effect on the susceptibility to apoptotic stimuli, obviating the requirement of MYCN and IFNg for apoptosis of subconfluent cells. Serum deprivation is the only stimulus needed to induce apoptosis in these cells. This strongly increased susceptibility to apoptosis was brought about by a comparatively little increase in ataxin-2 protein, suggesting that neuroblastoma cells maintaining high ataxin-2 levels in their proliferative state, such as Tet21N cells, require only a small degree of ataxin-2 upregulation in order to respond to apoptotic stimuli. Further evidence for an involvement of wild-type ataxin-2 in regulating apoptosis is provided by the finding that mutation of the polyglutamine tract results in a reduced proapoptotic activity.
Although not required, IFNg is able to accelerate ataxin-2-mediated apoptosis. IFNg-induced changes in gene expression may cooperate with ataxin-2 in triggering apoptosis. IFNg was reported to activate the CD95 system in neuroblastoma cells (Bernassola et al., 1999; Annicchiarico-Petruzzelli et al., 2001) , and several IFNg targets like PKR (Gil and Esteban, 2000) and DAP kinase (Cohen et al., 1997) have a proapoptotic function.
In vivo, we found high expression levels of ataxin-2 in neuroblastoma tumors without amplified MYCN gene. Most of these tumors also expressed procaspases 8 and 3. Especially high ataxin-2 levels were detected in stage-4s tumors, which regress spontaneously after a Ataxin-2 in apoptosis of neuroblastoma cellsprogressive phase (Berthold and Hero, 2000) . In contrast, MYCN-amplified tumors, which are often resistant to chemotherapy and go along with dismal prognosis, contain significantly less ataxin-2 protein. . In a previous study, 63% of MYCN-amplified neuroblastoma tumors were reported to have completely methylated CASP8 alleles (Teitz et al., 2000) . In vitro, loss of caspase-8 expression correlates with resistance to death-receptor-mediated apoptosis, and re-expression of caspase-8 restores sensitivity (Eggert et al., 2001; Fulda et al., 2001) . The MYCN-amplified neuroblastoma cell lines Kelly, NGP and CHP-134 have strongly reduced ataxin-2 protein levels compared to SH-EP cells and nonneuroblastoma cells such as 293 embryonic kidney cells and HeLa cells. Concomitantly, MYCN-amplified neuroblastoma cell lines do not undergo apoptosis following serum deprivation and IFNg exposure (I Wittke, unpublished data). Lack of procaspase-8 expression in Kelly, NGP and CHP-134 cells may not be sufficient to confer resistance to apoptosis induced by serum starvation, as embryonic fibroblasts obtained from CASP8À/À mice are still sensitive to serum deprivation (Varfolomeev et al., 1998) . In contrast to neuroblastoma cells with low ataxin-2 expression, SH-EP cells are sensitive to apoptosis following serum deprivation (van Golen et al., 2000 (van Golen et al., , 2001 . The observation that MYCN expression is required for apoptosis only in confluent Tet21N cells refines and extends previous findings (Lutz et al., 1998) . Collectively, it appears that in confluent nonproliferating cells, MYCN modulates the expression of genes that in proliferating cells are either active or inactive. These changes in gene expression apparently required for apoptosis may involve E2F transcription factors (Mac et al., 2000) , which also have been recognized as mediators of MYC-induced apoptosis (Leone et al., 2001; Muller et al., 2001) . Taken together, high protein levels of ataxin-2 seem to facilitate the induction of apoptosis in neuroblastoma cells. As MYCN accelerates cell death and confers sensitivity to confluent cell cultures, our observations suggest a requirement for MYCN-amplified neuroblastoma cells to downregulate endogenous ataxin-2 in order to acquire resistance to apoptosis. The detailed mechanisms in neuroblastoma cells where expression of wildtype ataxin-2, but not of mutant ataxin-2, actively promotes cell death will be addressed in future studies.
Materials and methods

Construction of the subtractive cDNA library
The subtractive cDNA library was generated with the PCR Select cDNA Subtraction Kit (BD-Clontech). Tester cDNA originated from Tet21N RNA harvested 2, 4, 12, 24 and 48 h after induction of apoptosis by IFNg and serum deprivation. Equal amounts of RNA from all time points were pooled prior to cDNA synthesis. Driver RNA was isolated in parallel from control cells that had not been exposed to IFNg.
Construction of pcDNA4HisMax-Sca2CAG(n)
The ataxin-2 coding sequence was isolated from pCINeoSca2CAG22 by restriction with NotI and SalI and cloned into pcDNA4HisMax (Invitrogen). Correct insertion was checked by sequencing. PcDNA4HisMax-Sca2CAG79 and pcDNAHisMax-Sca2CAGl were derived from this construct by exchange of a SacII cassette. The SacII fragment was excised from pcDNA1.1-Sca2CAG79 and pcDNA1.1-Sca2-CAGl, respectively.
Cell culture
Tet21N cells were cultivated in RPMI 1640 growth medium (27). Zeocint was added at a concentration of 250 mg/ml to cells transfected with pcDNA4HisMax (Invitrogen). Apoptosis in Tet21N cells was induced by reducing the FCS level to 0.5% and by adding 500 U/ml of recombinant IFNg (Roche). For the generation of stable cell clones, Tet21N cells were transfected with linearized pcDNA4HisMax-Sca2CAG(n) or pcDNA4HisMax (PvuI-restriction) using FuGenet (Roche). The cells were cultivated in the presence of Zeocint for at least 14 days before single colonies were picked.
Isolation and analysis of DNA DNA was extracted from cultivated cells by lysis with 1.25% SDS, proteinase K incubation and subsequent extraction with phenol/chloroform. In order to visualize the DNA ladder, 5 mg of DNA was digested with RNase, run on a 0.8% agarose gel and stained with ethidium bromide.
Cell death assays
For trypan blue assays, 5 Â 10 5 cells were seeded in 6 cm culture dishes in medium containing 10% FCS. After cell attachment, the medium was exchanged for medium with 0.5% FCS. At the indicated time points, cells were removed from the dishes by versene treatment, mixed with an equal volume of 0.1% trypan blue in PBS and counted in a Bu¨rker chamber. ZVAD-fmk and zFA-fmk (Calbiochem) were added at concentrations of 60 mm. MTT assays were performed as follows: 1000 or 5000 cells per well were seeded into 96-well plates in 200 ml of medium. At the indicated time points, MTT (Sigma) was added to the medium at a final concentration of 50 mg/ml. The cells were cultivated for an additional 4 h, followed by removal of medium and cell lysis with 95% isopropanol/5% acetic acid. Absorbance was measured in an ELx-800 ELISA reader (Bio-Tek Instruments) at 570 nm.
RNA extraction, Northern blots
Total RNA was isolated using TRIZOLt (Invitrogen-Life Technologies). Poly-A + -RNA was prepared using the Oligotex Kit (Qiagen). RNA samples were resolved on a 1% agarose gel containing formaldehyde and blotted on a nylon membrane (Hybondt-N, Amersham). Northern hybridizations were carried out in ULTRAhyb hybridization solution (Ambion). CDNA fragments of ataxin-2, cathepsin B, DAPAT, dynamin, filamin, CDK9 and b-actin were generated by PCR or restriction and labelled with a-32 P-dCTP (Amersham) using random priming and Klenow fragment (MBI). Blots were exposed to Biomax MS films (Kodak) for 3-8 h.
Protein extraction, Western blots
Total cellular protein was solubilized in lysis buffer (7 m urea, 1% Triton X-100, 100 mm DTT, 20 mm Tris-HCl, pH 8.5) and measured by a Bradford assay (BioRad). Before loading on 7.5% polyacrylamide gels, samples were boiled in one volume of loading buffer for 2 min. Proteins were blotted on PVDF membranes (Immobilont-P, Millipore) using 25 mm CAPSO, pH 10 or Towbin buffer (25 mm Tris, 192 mm glycine, 10% methanol) as transfer buffer. Transfer of equal amounts Ataxin-2 in apoptosis of neuroblastoma cellsof protein was checked by reversible Ponceau-S staining. Membranes were blocked in 1% blocking solution (Roche). First antibodies were applied in 0.5% blocking solution at concentrations of 0.5 mg/ml (ataxin-2, Transduction Labs), 1 mg/ml (MYCN, Pharmingen) or at a dilution of 1 : 10 (C15 antibody against caspase-8); the second antibody (polyclonal goat-antimouse conjugated to horseradish peroxidase, Pharmingen) was applied in 0.5% blocking solution at a dilution of 1 : 1000. Proteins were detected using the BM Chemiluminescence Substrate (Roche; films: HyperfilmtECLt, Amersham).
Immunofluorescence
Cells grown on coated glass slides were washed with PBS, fixed with 3.7% formaldehyde for 10 min and permeabilized in PBS containing 0.05% NP-40, 0.1% BSA for 5 min. The FITC-coupled a-Xpresst antibody (Invitrogen) was applied at a dilution of 1 : 500 in PBS containing 0.1% BSA for 1 h. Nuclei were stained with 50 ng/ml DAPI in 2 Â SSC for 2 min.
RT-PCR
DNase-treated RNA (1 mg) was reversely transcribed using SuperscriptIIt (Invitrogen-Life Technologies) and oligo-T priming. PCR was carried out with the primer pair 1052A and 1190B (Huynh et al., 2000) and Taq DNA polymerase (Promega). Conditions were: 1 min 951C, 5 cycles of 951C for 45 s, 651C for 30 s, 701C for 1 min, followed by 30 cycles of 951C for 45 s, 601C for 30 s and 701C for 1 min.
